• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

FDA warn­ing let­ters de­tail is­sues for man­u­fac­tur­ing sites in the US and In­dia

3 years ago
Pharma
FDA+

No­vo Nordisk drops two pro­grams as it plots We­govy come­back

3 years ago
Pharma

Al­lo­gene Over­land Bio­pharm com­pletes Shang­hai fa­cil­i­ty to man­u­fac­ture CAR-T prod­ucts

3 years ago
Pharma
Cell/Gene Tx

CVS, Wal­greens and Wal­mart reach near­ly $12B set­tle­ment over opi­oid epi­dem­ic

3 years ago
Law

For months Biden has tout­ed his win over phar­ma in the elec­tion lead-up. Will it help?

3 years ago
FDA+
Law

Sur­face On­col­o­gy lays off 20% as biotech halts CD39 work on one of its ‘crown jew­els’

3 years ago
People
R&D

In spin­ning out can­cer pipeline, Alk­er­mes cites In­fla­tion Re­duc­tion Ac­t's hy­po­thet­i­cal in­cen­tives for bi­o­log­ics R&D

3 years ago
Deals
R&D

Basilea’s can­cer pipeline slim­down con­tin­ues; Aque­s­tive looks to out­li­cense seizure drug in US

3 years ago
News Briefing

Rigel churns out an­oth­er late-stage clin­i­cal fail­ure — this time in Covid-19

3 years ago
R&D
Coronavirus

An NK cell ther­a­py biotech pulls IPO am­bi­tions weeks af­ter sec­ond tri­al clear­ance

3 years ago
Financing
Startups

CSL stacks up $4.5B in chips — with a $200M ante — to wa­ger on the next-gen mR­NA wave

3 years ago
Deals

ICER says it's fair for Bio­Marin and CSL to price in­com­ing he­mo­phil­ia gene ther­a­pies at $2M-$3M

3 years ago
Cell/Gene Tx

Up­dat­ed: GSK nabs pri­or­i­ty re­view on RSV vac­cine, kicks off show­down with Pfiz­er — while 'set­ting the bar high' on ...

3 years ago
R&D
Pharma

CFIUS re­view trig­gers de­lay on F-star's sale to Chi­nese play­er

3 years ago
Deals
China

Lead­ing a $60M launch round, RA Cap­i­tal backs an­oth­er 'toad ven­om' start­up

3 years ago
Financing
Startups

Ex­elix­is shells out $100M cash in a pair of deals, shoot­ing for dif­fer­ent takes on CD47, AD­Cs

3 years ago
Deals

Amid rev­enue dip, Pfiz­er CEO Al­bert Bourla is fo­cused on 'what's nex­t'

3 years ago
Pharma

FDA warns Ama­zon again for sell­ing un­ap­proved drugs on­line

3 years ago
FDA+

New JA­MA study digs in­to the rise of stack­ing FDA’s ex­pe­dit­ed pro­grams and des­ig­na­tions for new drugs

3 years ago
FDA+

Eli Lil­ly plans to make tirzepatide next big thing as phar­ma ex­pe­ri­ences 'un­prece­dent­ed' de­mand for the drug

3 years ago
Pharma

FDA clar­i­fies when spon­sors' ex­pand­ed ac­cess poli­cies need to be made pub­lic

3 years ago
FDA+

#CPHI22: As Sam­sung’s new plant comes on­line, it looks to ex­pand in Ko­rea and be­yond

3 years ago
Pharma
Manufacturing

HHS re­news 'call to ac­tion' with Covid boost­er ad spots

3 years ago
Pharma
Coronavirus

Col­lege ath­lete deals and phar­ma? Dex­com tests the wa­ters in a first move that opens new spokesper­son doors for ...

3 years ago
Pharma
Marketing
First page Previous page 429430431432433434435 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times